Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercury LaboratoriesBOM:538964 +4.57%76 PB Ratio is 1.68 as of Aug. 05, 2026, which is 10% below its 10-year median of 1.87. GuruFocus rates BOM:538964 with a GF Score™ of 76/100 and a GF Value™ of ₹832.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Mercury Laboratories ranks better than 56.4% on this metric.
Mercury Laboratories Ltd stock PB Ratio (=1.62) is close to 3-year low of 1.47.
The historical rank and industry rank for Mercury Laboratories's PB Ratio or its related term are showing as below:
BOM:538964'
s PB Ratio Range Over the Past 10 Years
Min: 0.92 Med: 1.87 Max: 3.05
Current: 1.62
During the past 13 years, Mercury Laboratories's highest PB Ratio was 3.05. The lowest was 0.92. And the median was 1.87.
BOM:538964's PB Ratio is ranked better than 56.4% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.915
vs BOM:538964: 1.62
During the past 12 months, Mercury Laboratories's average Book Value Per Share Growth Rate was 8.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Mercury Laboratories was 16.70% per year. The lowest was 8.40% per year. And the median was 11.45% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mercury Laboratories PB Ratio Related Terms
Mercury Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Mercury Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mercury Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mercury Laboratories (BOM:538964) has a PB Ratio of 1.68 as of Aug. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mercury Laboratories and its competitors. This is 10% below median its historical median of 1.87. Over the past decade, Mercury Laboratories' PB Ratio has ranged from 0.92 to 3.05. According to the industry distribution chart, Mercury Laboratories ranks #402 out of 922 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Mercury Laboratories' PB Ratio too high?
Mercury Laboratories' current PB Ratio of 1.68 is 10% below median its 10-year median of 1.87. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 3.05. The Drug Manufacturers industry median PB Ratio is 1.92. Mercury Laboratories' value of 1.68 is 12.3% below this industry median. Based on the distribution chart, Mercury Laboratories ranks #402 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mercury Laboratories has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mercury Laboratories' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercury Laboratories ranks #402 out of 922 companies for PB Ratio. This puts Mercury Laboratories in the upper half of its industry. The industry median PB Ratio is 1.92. Mercury Laboratories' value of 1.68 is 12.3% below this benchmark. Historically, Mercury Laboratories' own PB Ratio has ranged from 0.92 to 3.05 over the past decade. While the company's 10-year median is 1.87 vs. the industry median of 1.92, Mercury Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mercury Laboratories's current PB Ratio of 1.68 is 12.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mercury Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Laboratories's current PB Ratio is 1.68, which is 10% below median its own 10-year median of 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mercury Laboratories (BOM:538964) is currently considered Fairly Valued. The stock's GF Value™ is ₹832.71, compared to a current price of ₹812.50 — trading 2.4% below its estimated fair value. The current PB Ratio is 1.68, which is 10% below median its 10-year median of 1.87 and 12.3% below the Drug Manufacturers industry median of 1.92. Mercury Laboratories' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mercury Laboratories (BOM:538964), the current PB Ratio is 1.68 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Laboratories (BOM:538964) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Laboratories stock appears to be undervalued.
The current stock price of ₹812.50 is trading 2.4% below its estimated GF Value™ of ₹832.71.
GuruFocus considers Mercury Laboratories to be Fairly Valued.
Key valuation signals for BOM:538964:
PB Ratio: 1.68 (10% below median its 10-year median of 1.87)
GF Value™: ₹832.71 vs. price of ₹812.50 (2.4% below fair value)
Industry Position: 12.3% below the Drug Manufacturers median (#402 of 922)
No single metric tells the full story. See the BOM:538964 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and Internationally, of which key revenue is derived from sales made in India.
76GF Score
Get the complete analysis for BOM:538964
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538964 has been successfully added to your 
